Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUPRENORPHINE vs BRYNOVIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist; also exhibits high affinity but low intrinsic activity at mu-opioid receptors, producing analgesia and euphoria with a ceiling effect on respiratory depression.
Brynoxin is a potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.
Treatment of opioid dependence (Subutex, Suboxone),Moderate to severe pain (parenteral formulation, e.g., Buprenex),Off-label: Treatment of depression (as adjunctive therapy), chronic pain in opioid-tolerant patients, and neonatal abstinence syndrome (probable).
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
Sublingual tablet: 2-8 mg every 6-8 hours as needed for pain; for opioid use disorder: 12-16 mg once daily. Transdermal patch: 5-20 mcg/h applied every 7 days. IV/IM: 0.3 mg every 6-8 hours.
Adult: 150 mg orally twice daily.
Terminal elimination half-life is 24-60 hours (mean ~37 hours) due to enterohepatic recirculation and slow dissociation from mu-opioid receptors. Clinically, this allows for every-other-day or thrice-weekly dosing in maintenance therapy.
Terminal elimination half-life is 12 hours in patients with normal renal function; prolonged to 24-48 hours in moderate to severe renal impairment (Cr Cl < 30 m L/min).
Primarily hepatic via N-dealkylation to norbuprenorphine via CYP3A4, with minor contribution from CYP2C8; norbuprenorphine is active and further glucuronidated; undergoes extensive first-pass metabolism; mainly excreted in feces (as unchanged drug and metabolites) and to a lesser extent in urine.
Primarily metabolized via glucuronidation by UGT1A9 and UGT2B7; minor metabolism by CYP3A4.
Buprenorphine is primarily eliminated via biliary excretion of its metabolites, with approximately 70% of the dose recovered in feces as unchanged drug and metabolites. Renal elimination accounts for about 10-30%, primarily as metabolites.
Renal excretion accounts for 70% of the administered dose as unchanged drug; biliary/fecal excretion accounts for 30%.
Approximately 96% bound to alpha- and beta-globulins, with minimal binding to albumin.
85% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Volume of distribution is 2-4 L/kg (mean ~3.2 L/kg). High Vd indicates extensive tissue distribution, including sequestration in brain and adipose tissue.
1.5 L/kg, indicating extensive tissue distribution and penetration into peripheral compartments.
Sublingual: 30-55% (variable due to first-pass metabolism); Oral: ~15% (low due to extensive hepatic metabolism); Transdermal: ~15-20%; Intravenous/Intramuscular: 100%.
Oral: 75% (range: 60-90%) with minimal first-pass metabolism; intravenous: 100%.
No dosage adjustment required for mild to moderate impairment (GFR >30 m L/min). For severe impairment (GFR <30 m L/min), consider reducing dose and increasing interval; avoid in anuric patients.
Cr Cl 30-59 m L/min: 75 mg twice daily; Cr Cl 15-29 m L/min: 50 mg twice daily; Cr Cl <15 m L/min or dialysis: 25 mg once daily.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% and monitor. Child-Pugh C: contraindicated or use with extreme caution with significant dose reduction (e.g., 50-75% reduction).
Child-Pugh A: no adjustment; Child-Pugh B: 75 mg twice daily; Child-Pugh C: 50 mg twice daily.
For pain (≥2 years): sublingual tablet 2-6 mcg/kg every 4-8 hours; IV/IM 2-6 mcg/kg every 4-6 hours. For opioid use disorder (≥16 years): induction 2-4 mg, then titration to 12-16 mg once daily; safety in <16 years not established.
Children ≥12 years and ≥40 kg: 150 mg twice daily; <40 kg: 5 mg/kg/dose twice daily (max 150 mg/dose).
Initiate at lowest dose (e.g., sublingual 2 mg, transdermal 5 mcg/h) and titrate slowly due to increased sensitivity and risk of respiratory depression, falls, and cognitive impairment; monitor renal and hepatic function.
No specific dose adjustment, but monitor renal function; start at lower end of dosing range if renal impairment.
Risk of respiratory depression, particularly in non-opioid-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of serious harm or death with concomitant use of benzodiazepines or CNS depressants; requirement for patient access to emergency medical services and monitoring; risk of addiction, abuse, and misuse; risk of accidental exposure.
None.
Respiratory depression: ceiling effect exists, but risk increases with non-opioid-tolerant use or coadministration of CNS depressants,Potentiation of respiratory depression by benzodiazepines and alcohol,Neonatal opioid withdrawal syndrome: avoid prolonged use during pregnancy unless necessary,Adrenal insufficiency: risk with prolonged use,Androgen deficiency: may occur with chronic use,Hypotension, especially in hypovolemic patients,Biliary tract spasm: may cause constriction of sphincter of Oddi,Risk of misuse, abuse, and diversion
Ketoacidosis: Monitor for signs of ketoacidosis, including euglycemic ketoacidosis,Lower limb amputation: Consider risk factors prior to initiation; monitor for signs of infection or ulceration
Hypersensitivity to buprenorphine or any component of the formulation,Significant respiratory depression in non-opioid-tolerant patients,Acute or severe bronchial asthma,Known or suspected gastrointestinal obstruction (including paralytic ileus),Monoamine oxidase inhibitor (MAOI) use within past 14 days (relative contraindication; may precipitate serotonin syndrome),Mild to moderate hepatic impairment: use with caution; severe hepatic impairment: contraindicated
Severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease on dialysis,History of serious hypersensitivity reaction to brynoxin or any excipient in the formulation
No specific food interactions. Grapefruit juice may increase buprenorphine levels via CYP3A4 inhibition. Avoid excessive alcohol. Maintain a balanced diet to support overall health during treatment.
Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition. Avoid alcohol as it may increase hepatotoxicity risk. Take with food to reduce gastrointestinal upset.
FDA Pregnancy Category C. First trimester: No clear evidence of major malformations in human studies, but animal studies show increased risk of neural tube defects and skeletal anomalies at high doses. Second and third trimesters: Risk of neonatal opioid withdrawal syndrome (NOWS) with chronic use; may cause fetal respiratory depression if used near term.
First trimester: Human data limited; animal studies show embryotoxicity at supra-therapeutic doses. Avoid unless benefit outweighs risk. Second trimester: No specific malformation signal; monitor fetal growth. Third trimester: Risk of neonatal adaptation syndrome (irritability, feeding difficulties) at delivery if used near term.
Buprenorphine is excreted into breast milk with a milk-to-plasma ratio of approximately 0.6 to 1.2. It is generally considered compatible with breastfeeding, but infants should be monitored for sedation and respiratory depression, especially in high maternal doses or with concomitant CNS depressants.
Excreted in breast milk in low amounts (M/P ratio 0.2–0.4). Considered compatible with breastfeeding; monitor infant for sedation or gastrointestinal effects.
No routine dose adjustment is recommended, but dose may need to be increased due to increased clearance and volume of distribution in pregnancy, particularly in the third trimester. Monitor for withdrawal symptoms (e.g., craving, anxiety, abdominal cramping) and consider incremental dose increases (by 2-4 mg) if needed. Postpartum, dose should be titrated back to prepregnancy level over 1-2 weeks.
Due to increased volume of distribution and enhanced hepatic clearance in second and third trimesters, the dose may need to be increased by 20–40% to maintain therapeutic plasma concentrations. Therapeutic drug monitoring (trough levels) recommended every 2 weeks with target range 5–15 mcg/m L. Postpartum: reduce dose to pre-pregnancy level within first week.
Buprenorphine is a partial mu-opioid agonist with a ceiling effect on respiratory depression, making it safer than full agonists in overdose. It has high affinity for mu receptors, which can precipitate withdrawal if given to opioid-dependent patients already on full agonists. Sublingual administration avoids first-pass metabolism. Monitor liver function due to hepatotoxicity risk, especially with injectable forms. Long half-life allows every-other-day dosing in maintenance therapy. Naloxone is added in combination products to deter intravenous abuse.
Monitor renal function and electrolytes before and during therapy. Use with caution in patients with pre-existing cardiac disease due to risk of QT prolongation. Adjust dose in hepatic impairment (Child-Pugh B or C). Contraindicated with strong CYP3A4 inducers.
Take buprenorphine exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not use alcohol, benzodiazepines, or other sedatives while on buprenorphine as it can cause severe drowsiness, respiratory depression, or coma.,Avoid driving or operating heavy machinery until you know how buprenorphine affects you.,Do not stop abruptly; withdrawal symptoms may occur. Taper under medical supervision.,Store safely out of reach of children; accidental ingestion can be fatal.,Inform your doctor if you have liver disease, breathing problems, or are pregnant.,If you miss a dose, take it as soon as possible; skip if almost time for next dose. Do not double dose.
Take exactly as prescribed; do not skip doses or double up.,Avoid grapefruit and grapefruit juice during treatment.,Report any signs of infection, unusual bruising, or yellowing of skin or eyes.,Use effective contraception during treatment and for 3 months after last dose.,Do not drive if you experience dizziness or blurred vision.
"Buprenorphine, a partial mu-opioid receptor agonist with ceiling effects on respiratory depression, coadministered with Ketobemidone, a full mu-opioid agonist, may produce additive central nervous system (CNS) depression. This synergistic effect can lead to profound sedation, respiratory depression, coma, and death, especially when doses are escalated or in the presence of other CNS depressants. The interaction is particularly dangerous due to buprenorphine's high affinity for mu receptors potentially displacing Ketobemidone and precipitating withdrawal, while simultaneously contributing to CNS depressant effects."
"Buprenorphine, a partial mu-opioid receptor agonist, and triflupromazine, a phenothiazine antipsychotic with strong central nervous system (CNS) depressant properties, exert additive CNS depression when coadministered. This can lead to excessive sedation, respiratory depression, hypotension, and increased risk of coma or death, particularly in elderly or compromised patients. The interaction reduces psychomotor function and may potentiate other adverse effects such as orthostatic hypotension and extrapyramidal symptoms."
"Buprenorphine, a partial mu-opioid receptor agonist, can inhibit CYP3A4 isoenzymes, thereby reducing the hepatic metabolism of Midostaurin, a multikinase inhibitor primarily metabolized by CYP3A4. This results in elevated plasma concentrations of Midostaurin, increasing the risk of dose-dependent toxicities such as QT prolongation, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of Midostaurin toxicity and consider dose adjustments."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUPRENORPHINE vs BRYNOVIN, answered by our medical review team.
BUPRENORPHINE is a Opioid Partial Agonist that works by Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist; also exhibits high affinity but low intrinsic activity at mu-opioid receptors, producing analgesia and euphoria with a ceiling effect on respiratory depression.. BRYNOVIN is a Opioid Partial Agonist that works by Brynoxin is a potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUPRENORPHINE and BRYNOVIN depend on the specific clinical indication. These are both Opioid Partial Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUPRENORPHINE is: Sublingual tablet: 2-8 mg every 6-8 hours as needed for pain; for opioid use disorder: 12-16 mg once daily. Transdermal patch: 5-20 mcg/h applied every 7 days. IV/IM: 0.3 mg every 6-8 hours.. The standard adult dose of BRYNOVIN is: Adult: 150 mg orally twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUPRENORPHINE and BRYNOVIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUPRENORPHINE is classified as Category C. FDA Pregnancy Category C. First trimester: No clear evidence of major malformations in human studies, but animal studies show increased risk of neural tube defects and skeletal ano. BRYNOVIN is classified as Category C. First trimester: Human data limited; animal studies show embryotoxicity at supra-therapeutic doses. Avoid unless benefit outweighs risk. Second trimester: No specific malformation . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.